arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Veradermics, Inc

MANE
$114.40 ▲ +5.86 (+5.40%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
5 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
89
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Veradermics, Inc shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $2.6B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -7.6%
FCF / Share $-0.93
Trailing P/E
Price / Book 10.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-27.23M
↓ -119.6%
FCF / Share Free cash flow per share
$-0.93
↑ +94.8%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
97
Cash Quality
67

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 5 quarters